𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study

✍ Scribed by Victoria S. Benson; Kirstin Pirie; Jane Green; Diana Bull; Delphine Casabonne; Gillian K. Reeves; Valerie Beral; for the Million Women Study Collaborators

Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
217 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We examined the relation between the use of hormone replacement therapy (HRT) and the incidence of central nervous system (CNS) tumours in a large prospective study of 1,147,894 postmenopausal women. Women were aged 56.6 years on average at entry, and HRT use was recorded at recruitment and updated, where possible, about 3 years later. During a mean follow‐up of 5.3 years per woman, 1,266 CNS tumours were diagnosed, including 557 gliomas, 311 meningiomas and 117 acoustic neuromas. Compared with never users of HRT, the relative risks (RRs) for all incident CNS tumours, gliomas, meningiomas and acoustic neuromas in current users of HRT were 1.20 (95% CI: 1.05–1.36), 1.09 (95% CI: 0.89–1.32), 1.34 (95% CI: 1.03–1.75) and 1.58 (95% CI: 1.02–2.45), respectively, and there was no significant difference in the relative risks by tumour type (heterogeneity p = 0.2). In past users of HRT the relative risk was 1.07 (95% CI: 0.93–1.24) for all CNS tumours. Among current users of HRT, there was significant heterogeneity by the type of HRT with the users of oestrogen‐only HRT at higher risk of all CNS tumours than users of oestrogen–progestagen HRT (RR = 1.42, 95% CI: 1.21–1.67 versus RR = 0.97, 95% CI: 0.82–1.16) (heterogeneity p < 0.001). Among current users of oestrogen‐only and oestrogen–progestagen HRT, there was no significant heterogeneity by duration of use, hormonal constituent or mode of administration of HRT.

📜 SIMILAR VOLUMES

Hormone replacement therapy and incidenc
Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study
✍ Kjersti Bakken; Elin Alsaker; Anne Elise Eggen; Eiliv Lund 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 2 views

## Abstract Increasing use of HRT over the last 2 decades could have contributed to the increasing incidence of cancer in women. Our aim was to investigate the relation between use of HRT and risk of hormone‐dependent cancers in a Norwegian cohort of women. The Norwegian Women and Cancer (NOWAC) st

Increased incidence of small and well-di
Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy
✍ Jonas Manjer; Janne Malina; Göran Berglund; Lennart Bondeson; Jens Peter Garne; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 52 KB 👁 1 views

Exposure to hormone-replacement therapy (HRT) has consistently been associated with an increased incidence of breast cancer, particularly of small tumours. Other tumour characteristics in relation to HRT have received less scientific attention. Our aim in this population-based prospective cohort stu

Hormone replacement therapy and breast c
Hormone replacement therapy and breast cancer in former users of oral contraceptives—The Norwegian Women and Cancer study
✍ Eiliv Lund; Kjersti Bakken; Vanessa Dumeaux; Vegard Andersen; Merethe Kumle 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 66 KB 👁 1 views

## Abstract Combined estrogen–progestin menopausal therapy (HRT) and combined estrogen–progestin contraceptives (OC) both increase breast cancer risk during current use and a few years after. We investigated risk of breast cancer in women who were users of HRT dependant on former history of OC use

Hormone replacement therapy and the risk
Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening
✍ Ingemar Persson; Erik Thurfjell; Reinhold Bergström; Lars Holmberg 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 37 KB 👁 3 views

There is concern that hormone replacement therapy (HRT) increases the risk of breast cancer. We undertook a casecontrol study of this risk relationship within a cohort of 40-to 74-year-old women in Uppsala County, Sweden, who participated in mammography screening. Incident cases of breast cancer wer

Effective preventive central nervous sys
Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia : The ISRAEL National Study report
✍ Batia Stark; Rivka Sharon; Gideon Rechavi; Dina Attias; Ami Ballin; Gabriel Civi 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

BACKGROUND. Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies. Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups. In